Research progress of 18 F-Flurpiridaz PET myocardial perfusion imaging / 中华核医学与分子影像杂志

ABSTRACT

PET myocardial perfusion imaging ( MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease ( CAD) . However, the wide application of common PET MPI a-gents ( 15 O-H2 O, 13 N-NH3 ·H2 O, 82 Rb) in clinic is limited by their inherent shortcomings. The develop-ment of 18 F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18 F-Flurpiridaz has important properties ( high myocardial up-take, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical appli-cation prospect. In this paper, the present application and progress of 18 F-Flurpiridaz PET MPI are re-viewed.